Raj Satkunasivam, MD, MS, FRCSC

Raj Satkunasivam, MD, MS, FRCSC, Houston Methodist Hospital

Articles by Raj Satkunasivam, MD, MS, FRCSC

How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?

Raj Satkunasivam, MD, MS, FRCSCNon-Muscle Invasive Urothelial Carcinoma | September 8, 2023

Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.

Dr. Raj Satkunasivam on Neoadjuvant Sasanlimab and SBRT for Cisplatin-Ineligible MIBC

Raj Satkunasivam, MD, MS, FRCSCMuscle Invasive Urothelial Carcinoma | August 9, 2023

Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab.

Dr. Raj Satkunasivam on MIBC Neoadjuvant Approaches for Local, Distant Control

Raj Satkunasivam, MD, MS, FRCSCMuscle Invasive Urothelial Carcinoma | August 9, 2023

Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.